SemBioSys Genetics Inc. (SemBioSys) is a plant-based technology development company that utilizes its renewable, patented, plant seed-based oilbody genetic expression and manufacturing technology platforms to develop, manufacture and commercialize healthy living, animal health and pharmaceutical products. It produces oils and proteins from oil seeds and used to make plant-based general health, functional food, nutraceutical, animal health and pharmaceutical products using its manufacturing systems. In collaboration with its partner, Arcadia BioSciences Inc., the Company used its technology platform to develop a safflower oil containing omega-6 fatty acid gamma linolenic acid (GLA). Its biopharmaceutical pipeline includes Biosimilar Insulin for diabetes and Apo AIMilano for atherosclerotic cardiovascular disease. As of December 31, 2011, SemBioSys owned 30% interest of Tasly-SemBioSys Bio-Pharmaceutical Technology Co. Ltd.